1627522-99-9

Upstream product

• 1627522-92-2 3-chloro-N-(4-methoxyphenyl)-6-nitroquinoxalin-2-amine 
• 2379-60-4 2,3-dichloro-6-nitroquinoxaline 
• 2379-56-8 6-nitro-1,2,3,4-tetrahydroquinoxaline-2,3-dione 
• 104-94-9 4-methoxy-aniline 
• 15804-19-0 quinoxaline-2,3-dione 
• 95-54-5 1,2-diamino-benzene 
• 1627522-93-3 3-((4-methoxyphenyl)amino)-7-nitroquinoxalin-2(1H)-one 
• 1627522-94-4 7-amino-3-((4-methoxyphenyl)amino)quinoxalin-2(1H)-one 
• 3173-53-3 Cyclohexyl isocyanate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold

In an effort to develop ATP-competitive VEGFR-2 selective inhibitors, a series of new quinoxaline-based derivatives was designed and synthesized. The target compounds were biologically evaluated for their inhibitory activity against VEGFR-2. The design of the target compounds was accomplished after a profound study of the structure activity relationship (SAR) of type-II VEGFR-2 inhibitors. Among the synthesized compounds, 1-(2-((4-methoxyphenyl)amino)-3- oxo-3,4 dihydroquinoxalin-6-yl)-3-phenylurea (VIIa) displayed the highest inhibitory activity against VEGFR-2. Molecular modeling study involving molecular docking and field alignment was implemented to interpret the variable inhibitory activity of the newly synthesized compounds.